(Q38118053)

English

Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews

scientific article published on August 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Brian G. Feagan

1

object named as

Brian G Feagan

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

author name string

Nilesh Chande

2

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

John K MacDonald

3

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

publication date

1 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Inflammatory Bowel Diseases

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

2031-2040

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

An oral preparation to release drugs in the human colon

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Cortisone in ulcerative colitis; final report on a therapeutic trial.

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E3182920108

21 January 2018

Identifiers

10.1097/MIB.0B013E3182920108

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38118053&oldid=1742670310"